Postpartum Depression (PPD)NCT06682689
Investigation of TVNS Administration on Postpartum Mental Health
A study testing transcutaneous vagus nerve stimulation in people with Postpartum Depression (PPD) and Postpartum Anxiety, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
The aim of the study is to explore whether transcutaneous vagus nerve stimulation (tVNS) may be effective in preventing mood swings and depressive symptoms in the postpartum phase, as well as serving as a supplementary intervention in cases where mood symptoms develop. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Postpartum Depression (PPD), Postpartum Anxiety, Postpartum Sadness
- What is being tested?
- transcutaneous vagus nerve stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteGermany
- Study dates
- Nov 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- No malformation of fetal organs (no abnormalities detected during "organ screening").
- Ability to provide written consent for themselves.
- Sufficient German language skills to communicate and understand study procedures.
Who cannot join
- Exclusion criteria for tVNS use (i.e., pregnancy, active implants such as cochlear implants or cardiac pacemakers, cerebral shunts, skin problems, cardiovascular health issues).
- Cardiac arrhythmias or coronary heart disease.
- Neurological disorders.
- Current diagnosis or episode of a mood disorder.
- Diagnosed schizophrenia spectrum and other psychotic disorders.
- Severe substance use disorders.
- Individual exclusion may also occur based on other health issues if the study clinician determines that participation in the study may pose a disadvantage for the participant or the child.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Hospital Tuebingen; Department of Psychiatry and Psychotherapy
Tübingen, Baden-Wurttemberg, 72076
Julia Siodmiak, M.sc., +49 07071 29-86119, julia.siodmiak@med.uni-tuebingen.de
Birgit Derntl, Prof., PhD, M.sc.
About this study
Official title: Integrative Investigation of Transcutaneous Vagus Nerve Stimulation: Impact on Postpartum Mental Health Through Wearable Technology, Hormonal Analysis and Modulatory Factors
The aim of the study is to explore whether transcutaneous vagus nerve stimulation (tVNS) may be effective in preventing mood swings and depressive symptoms in the postpartum phase, as well as serving as a supplementary intervention in cases where mood symptoms develop. The study will investigate the effects of tVNS intervention during the first 12 weeks postpartum. Pregnant women will be recruited for the study, and the intervention will begin shortly after giving birth. Participants will receive different instructions on how to use the tVNS device. Additional parameters such as physiological functions, chronic stress, hormones, environment, and personality traits will also be assessed.
Read the detailed description
The study uses a crossover, repeated-measures, within-subject, and between-subject placebo and active control design. Three groups of women who have recently given birth will receive either high-intensity tVNS, low-intensity tVNS, or no stimulation intervention for six weeks. After this period, the two tVNS groups will switch protocols for another six weeks. Participants will also undergo a battery of psychometric and neuropsychological tests at multiple time points. By applying a multilevel approach, the investigators will assess changes in postpartum mood and mental state from subjective (daily mood assessments, psychometric tests), cognitive (neuropsychological tests), physiological (heart rate, sleep patterns), and endocrine (cortisol, sex hormones) perspectives.
Throughout the study, all participants will answer app-based ecological momentary assessments (EMA) to monitor mood fluctuations after stimulation and compare outcomes. Participants' partners will be invited to take part in the study if they wish; they will complete questionnaires regarding their mental health and the perceived support they provide. During the initial screening, participants will receive detailed information about the study, and inclusion and exclusion criteria will be evaluated.
At the first meeting (T1), informed broad consent will be obtained, and the study will be explained in detail. Instructions for using the tVNS devices will be provided based on group assignments. Participants will complete questionnaires, undergo a short neuropsychological test, and provide hair samples for cortisol concentration analysis.
After giving birth, participants (or their partners, with permission) will notify the researchers, and each woman in the experimental tVNS groups will receive a package containing the stimulator and access to usage tutorials and instructions. All participants will also receive smartwatches with usage instructions.
The main study will include 120 women who have recently given birth, randomly assigned to one of three groups:
Group one (High-low tVNS) will first receive an active, high-intensity tVNS stimulation protocol for six weeks at a self-chosen level below the pain threshold and will be advised to use it for up to four hours a day (as per the device manual's full and maximal stimulation session). Precise instructions and protocols to assess the stimulation intensity will be given beforehand. After six weeks (T2), they will switch to the low-intensity tVNS protocol used by group two.
Group two (Low-high tVNS) will use the device at the lowest possible intensity of 0,1 milliampere. This intensity equals the intensity of stimulation during the "OFF" Phase, for more details see "Arms and interventions"". After six weeks, participants will switch protocol for the one provided at the begging for group one for the remaining six weeks.
The device is pre-programmed to stimulate with constant parameters (except for intensity), and to minimize placebo effects, participants will be informed that different protocols with varying sensations are being tested.
Group three (No stimulation) will not receive any tVNS stimulation. Their mood and symptoms will be assessed similarly to the other two groups, and physiological measures will be monitored via smartwatch and hair sampling.
At week six (T2; around the 6th-7th week postpartum), participants from all groups will visit the lab to complete questionnaires, provide hormone samples, and undergo neuropsychological assessments.
During the experimental phase, participants will report daily on their current mood. They will continue to complete repeated questionnaires assessing their mental health, quality of life, sleep quality, and symptoms of depression and anxiety. At two postpartum time points (T2 and T3; weeks 6 and 12 after parturition), participants will be asked to return for additional sessions where blood will be drawn for hormonal analysis, questionnaires will be repeated, and neuropsychological testing will be performed. At week 12, hair samples will again be collected for cortisol concentration analysis.
A voluntary online follow-up is planned after the study. At 6 and 9 months postpartum, participants will be invited to complete some of the standardised questionnaires, previously administered earlier in the study. These questionnaires will assess various aspects of their current state, including mental health, physical well-being, and parenting stress
The study utilizes the CE-certified tVNS® E device to non-invasively stimulate the vagus nerve, in compliance with European safety and performance standards (Class IIa, based on (EU) 2017/745 for medical devices, classified as a short-term, active therapeutic, non-invasive medical device under rule 9). This device stimulates the vagus nerve non-surgically by targeting the auricular branch of the vagus nerve, which interfaces with the skin at the cymba conchae of the external ear. The tVNS® E is approved for use in healthy participants, as well as for the following conditions (without restrictions for healthy participants, provided tVNS exclusion criteria are followed): treatment of seizures in pharmaco-resistant epilepsy with focal and/or generalized seizures (to reduce seizure frequency); adjunctive treatment of depression; treatment of emotional outbursts in Prader-Willi syndrome (to reduce frequency); adjunctive treatment of chronic migraine (to reduce headache frequency); and prophylactic migraine therapy for patients with chronic migraines who refuse or do not tolerate prophylactic medication (tVNS® E Instruction for Use, Version 1.6, 2023-01-30).
- Being tested
- transcutaneous vagus nerve stimulation
- Keywords
- tVNS, Transcutaneous vagus nerve stimulation, Postpartum, PPD, Depression
- Medical subject headings
- Depression, Postpartum, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcutaneous vagus nerve stimulationDevice
Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
| Study group | Role | What they receive |
|---|---|---|
| High-low tVNS | Experimental | Participants in this group will be instructed to use the tVNS device every day for the first six weeks according to the manufacturer's guidelines, at an intensity where they can feel a tingling sensation but below the pain threshold. After six weeks (T2) of intervention, they will be asked to switch to a different protocol for the next six weeks, using the device at the lowest possible intensity. Additional instructions will be provided, and they will be informed that this stimulation uses different parameters set by the research team. Receives: Device: transcutaneous vagus nerve stimulation |
| Low-high tVNS | Active comparator | Participants in this group will receive the inverted intervention, with the first six weeks of stimulation at the lowest possible intensity (0.1 mA) with the same instructions regarding duration of stimulations, followed by six weeks of high-intensity stimulation as instructed by the manufacturer. Receives: Device: transcutaneous vagus nerve stimulation |
| No tVNS | No intervention | This group of participants will be included in all measurements (T1-T3) and check-ups, except for the tVNS stimulation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
tVNS-induced changes in postpartum depression symptoms
To evaluate the effect of transcutaneous vagus nerve stimulation (tVNS) on depressive symptoms, as measured by the Edinburgh Postpartum Depression Scale (EPDS), which ranges from 0 to 30, with higher scores indicating more severe depressive symptoms. A standard cut-off score of 12-13 is typically used to indicate probable depressive symptoms. The total EPDS score will be assessed at multiple time points throughout the study, allowing for the comparison of changes in depressive symptom trajectories across conditions (tVNS vs. control). This design aims to capture differences in the development and progression of depressive symptoms between groups over the course of pregnancy and postpartum.
Measured: Measured during pregnancy (T1), 6 weeks after birth (T2), and 12 weeks after birth (T3)]
tVNS-induced changes in the daily mood
The study will track and analyze the daily trajectory of mood changes-both positive and negative-from a baseline period prior to the 6-week transcutaneous vagus nerve stimulation (tVNS) intervention and throughout the intervention period, with assessments concluding on the final day of the intervention. Daily mood changes and stability will be measured using the Positive and Negative Affect Schedule (PANAS), administered through app-based ecological momentary assessment (EMA). Each item on the PANAS is rated on a 5-point Likert scale, ranging from 1 ("gar nichts" / "not at all") to 5 ("äußerst" / "extremely"), with higher scores reflecting a greater intensity of the specified mood. Positive affect (PA) scores represent more positive mood states (higher scores indicating better mood), while negative affect (NA) scores indicate the severity of negative mood states (higher scores representing worse mood).
The analysis will focus on identifying trends, patterns, and fluctuations in mood
Measured: From the recruitment through first 12 weeks of postpartum period
Secondary outcomes (8)
Intervention acceptance analysis
Using a mixed-method approach, including compliance analysis (tracking the frequency and duration of tVNS device use), retention analysis (comparing retention and dropout rates between groups at different time points), and post-intervention questionnaire-based data on participants' satisfaction with the intervention (assessing the burden of the intervention, side effects, and participants' theoretical willingness to recommend it to others).
Measured: through study completion, an average of 6 months
Heart-rate variability changes
HRV will be assessed through smartwatches, with analyses focusing on tVNS-induced changes compared to controls using RMSSD (Root Mean Square of Successive Differences), SDNN (Standard Deviation of NN intervals), and frequency-domain methods.
Measured: From the recruitment through first 12 weeks of postpartum period
Subjective sleep quality changes
Subjective sleep quality will be assessed monthly using the Pittsburgh Sleep Quality Index (PSQI), along with an ecological momentary assessment (EMA) question about sleep quality. Group comparisons will determine whether tVNS induces changes in sleep quality compared to control conditions.
In scoring the PSQI, seven component scores are derived, each rated from 0 (no impairment) to 3 (severe impairment). The component scores are summed to produce a global score (range 0 to 21), with higher scores indicating poorer sleep quality.
Measured: through study completion, an average of 6 months
Objective sleep quality
Sleep quality (duration, depth, and regularity) will be measured objectively using smartwatch data, focusing on tVNS-induced changes compared to the control group. Sleep duration will be measured in hours and minutes, sleep depth will be assessed based on time spent in different sleep stages (light sleep, deep sleep, and REM) in minutes, and sleep regularity will be evaluated by the variability in sleep and wake times, also in hours and minutes. Those submeasures will be further analysed to an overall sleep quality outcome
Note: While smartwatches provide estimates, their limitations in accuracy are acknowledged, and subjective data will be triangulated with these measures.
Measured: through study completion, an average of 6 months
Postpartum depression diagnosis (clinical threshold)
The number of women in each group who develop clinical threshold scores on the EPDS will be compared to assess whether tVNS reduces the risk of postpartum depression compared to controls.
Measured: From the birth of the child to the end of the study (12 weeks)
Objective measure of chronic stress
Hair cortisol concentrations will be measured twice (T1 during pregnancy, and T3 at 12 weeks postpartum) to assess tVNS-induced changes in chronic stress levels from past three months compared to controls. Individual events causing massive changes in cortisol concentration will be noted.
Measured: Two measurements: During pregnancy (T1) and 12 weeks postpartum (T3)
Subjective chronic stress levels
Total score on the Trier inventory for chronic stress (TICS; Schulz et al., 2004)
Measured: Three times: During 1st visit, at 6 weeks postpartum and 12 weeks after birth
Daily activity changes induced by tVNS
Daily activity will be measured via smartwatch data, focusing on activity level changes between the tVNS and control groups.
Measured: From the recruitment through first 12 weeks of postpartum period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study startNov 2024 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postpartum Depression (PPD)Studies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Collaborators
- German Center for Mental Health
- Responsible party
- Sponsor
- Investigators
- Birgit Derntl, Prof., PhD, Principal investigator, University Hospital TuebingenNils Kroemer, Prof., Dr. rer. nat., Principal investigator, University Hospital Tuebingen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06682689
- Sponsor's protocol ID
- TUE/858/2023BO2
- Status last verified
- Sep 2024
- First submitted
- 6 Nov 2024
- Last updated
- 12 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The individual participant data (IPD) will be anonymized and shared in accordance with the GDPR. Data will be shared to the extent that re-identification is not possible.
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Integrative Investigation of Transcutaneous Vagus Nerve Stimulation: Impact on Postpartum Mental Health Through Wearable Technology, Hormonal Analysis and Modulatory Factors
- ClinicalTrials.gov ID
- NCT06682689
- Acronym / sponsor ID
- TUE/858/2023BO2
- Keywords
- tVNS, Transcutaneous vagus nerve stimulation, Postpartum, PPD, Depression
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Collaborators
- German Center for Mental Health
- Study start
- Nov 2024 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to explore whether transcutaneous vagus nerve stimulation (tVNS) may be effective in preventing mood swings and depressive symptoms in the postpartum phase, as well as serving as a supplementary intervention in cases where mood symptoms develop. The study will investigate the effects of tVNS intervention during the first 12 weeks postpartum. Pregnant women will be recruited for the study, and the intervention will begin shortly after giving birth. Participants will receive different instructions on how to use the tVNS device. Additional parameters such as physiological functions, chronic stress, hormones, environment, and personality traits will also be assessed.
Detailed description
The study uses a crossover, repeated-measures, within-subject, and between-subject placebo and active control design. Three groups of women who have recently given birth will receive either high-intensity tVNS, low-intensity tVNS, or no stimulation intervention for six weeks. After this period, the two tVNS groups will switch protocols for another six weeks. Participants will also undergo a battery of psychometric and neuropsychological tests at multiple time points. By applying a multilevel approach, the investigators will assess changes in postpartum mood and mental state from subjective (daily mood assessments, psychometric tests), cognitive (neuropsychological tests), physiological (heart rate, sleep patterns), and endocrine (cortisol, sex hormones) perspectives.
Throughout the study, all participants will answer app-based ecological momentary assessments (EMA) to monitor mood fluctuations after stimulation and compare outcomes. Participants' partners will be invited to take part in the study if they wish; they will complete questionnaires regarding their mental health and the perceived support they provide. During the initial screening, participants will receive detailed information about the study, and inclusion and exclusion criteria will be evaluated.
At the first meeting (T1), informed broad consent will be obtained, and the study will be explained in detail. Instructions for using the tVNS devices will be provided based on group assignments. Participants will complete questionnaires, undergo a short neuropsychological test, and provide hair samples for cortisol concentration analysis.
After giving birth, participants (or their partners, with permission) will notify the researchers, and each woman in the experimental tVNS groups will receive a package containing the stimulator and access to usage tutorials and instructions. All participants will also receive smartwatches with usage instructions.
The main study will include 120 women who have recently given birth, randomly assigned to one of three groups:
Group one (High-low tVNS) will first receive an active, high-intensity tVNS stimulation protocol for six weeks at a self-chosen level below the pain threshold and will be advised to use it for up to four hours a day (as per the device manual's full and maximal stimulation session). Precise instructions and protocols to assess the stimulation intensity will be given beforehand. After six weeks (T2), they will switch to the low-intensity tVNS protocol used by group two.
Group two (Low-high tVNS) will use the device at the lowest possible intensity of 0,1 milliampere. This intensity equals the intensity of stimulation during the "OFF" Phase, for more details see "Arms and interventions"". After six weeks, participants will switch protocol for the one provided at the begging for group one for the remaining six weeks.
The device is pre-programmed to stimulate with constant parameters (except for intensity), and to minimize placebo effects, participants will be informed that different protocols with varying sensations are being tested.
Group three (No stimulation) will not receive any tVNS stimulation. Their mood and symptoms will be assessed similarly to the other two groups, and physiological measures will be monitored via smartwatch and hair sampling.
At week six (T2; around the 6th-7th week postpartum), participants from all groups will visit the lab to complete questionnaires, provide hormone samples, and undergo neuropsychological assessments.
During the experimental phase, participants will report daily on their current mood. They will continue to complete repeated questionnaires assessing their mental health, quality of life, sleep quality, and symptoms of depression and anxiety. At two postpartum time points (T2 and T3; weeks 6 and 12 after parturition), participants will be asked to return for additional sessions where blood will be drawn for hormonal analysis, questionnaires will be repeated, and neuropsychological testing will be performed. At week 12, hair samples will again be collected for cortisol concentration analysis.
A voluntary online follow-up is planned after the study. At 6 and 9 months postpartum, participants will be invited to complete some of the standardised questionnaires, previously administered earlier in the study. These questionnaires will assess various aspects of their current state, including mental health, physical well-being, and parenting stress
The study utilizes the CE-certified tVNS® E device to non-invasively stimulate the vagus nerve, in compliance with European safety and performance standards (Class IIa, based on (EU) 2017/745 for medical devices, classified as a short-term, active therapeutic, non-invasive medical device under rule 9). This device stimulates the vagus nerve non-surgically by targeting the auricular branch of the vagus nerve, which interfaces with the skin at the cymba conchae of the external ear. The tVNS® E is approved for use in healthy participants, as well as for the following conditions (without restrictions for healthy participants, provided tVNS exclusion criteria are followed): treatment of seizures in pharmaco-resistant epilepsy with focal and/or generalized seizures (to reduce seizure frequency); adjunctive treatment of depression; treatment of emotional outbursts in Prader-Willi syndrome (to reduce frequency); adjunctive treatment of chronic migraine (to reduce headache frequency); and prophylactic migraine therapy for patients with chronic migraines who refuse or do not tolerate prophylactic medication (tVNS® E Instruction for Use, Version 1.6, 2023-01-30).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High-low tVNS | Experimental | Device: transcutaneous vagus nerve stimulationParticipants in this group will be instructed to use the tVNS device every day for the first six weeks according to the manufacturer's guidelines, at an intensity where they can feel a tingling sensation but below the pain threshold. After six weeks (T2) of intervention, they will be asked to switch to a different protocol for the next six weeks, using the device at the lowest possible intensity. Additional instructions will be provided, and they will be informed that this stimulation uses different parameters set by the research team. |
| Low-high tVNS | Active comparator | Device: transcutaneous vagus nerve stimulationParticipants in this group will receive the inverted intervention, with the first six weeks of stimulation at the lowest possible intensity (0.1 mA) with the same instructions regarding duration of stimulations, followed by six weeks of high-intensity stimulation as instructed by the manufacturer. |
| No tVNS | No intervention | –This group of participants will be included in all measurements (T1-T3) and check-ups, except for the tVNS stimulation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- No malformation of fetal organs (no abnormalities detected during "organ screening").
- Ability to provide written consent for themselves.
- Sufficient German language skills to communicate and understand study procedures.
Key exclusion criteria (7 listed)
- Exclusion criteria for tVNS use (i.e., pregnancy, active implants such as cochlear implants or cardiac pacemakers, cerebral shunts, skin problems, cardiovascular health issues).
- Cardiac arrhythmias or coronary heart disease.
- Neurological disorders.
- Current diagnosis or episode of a mood disorder.
- Diagnosed schizophrenia spectrum and other psychotic disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcutaneous vagus nerve stimulationTwo groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use. | Device | High-low tVNS, Low-high tVNS |
Primary outcome
tVNS-induced changes in postpartum depression symptoms
Time frame: Measured during pregnancy (T1), 6 weeks after birth (T2), and 12 weeks after birth (T3)]
To evaluate the effect of transcutaneous vagus nerve stimulation (tVNS) on depressive symptoms, as measured by the Edinburgh Postpartum Depression Scale (EPDS), which ranges from 0 to 30, with higher scores indicating more severe depressive symptoms. A standard cut-off score of 12-13 is typically used to indicate probable depressive symptoms. The total EPDS score will be assessed at multiple time points throughout the study, allowing for the comparison of changes in depressive symptom trajectories across conditions (tVNS vs. control). This design aims to capture differences in the development and progression of depressive symptoms between groups over the course of pregnancy and postpartum.
tVNS-induced changes in the daily mood
Time frame: From the recruitment through first 12 weeks of postpartum period
The study will track and analyze the daily trajectory of mood changes-both positive and negative-from a baseline period prior to the 6-week transcutaneous vagus nerve stimulation (tVNS) intervention and throughout the intervention period, with assessments concluding on the final day of the intervention. Daily mood changes and stability will be measured using the Positive and Negative Affect Schedule (PANAS), administered through app-based ecological momentary assessment (EMA). Each item on the PANAS is rated on a 5-point Likert scale, ranging from 1 ("gar nichts" / "not at all") to 5 ("äußerst" / "extremely"), with higher scores reflecting a greater intensity of the specified mood. Positive affect (PA) scores represent more positive mood states (higher scores indicating better mood), while negative affect (NA) scores indicate the severity of negative mood states (higher scores representing worse mood). The analysis will focus on identifying trends, patterns, and fluctuations in mood
8 secondary outcomes
Intervention acceptance analysis
Time frame: through study completion, an average of 6 months
Heart-rate variability changes
Time frame: From the recruitment through first 12 weeks of postpartum period
Subjective sleep quality changes
Time frame: through study completion, an average of 6 months
Objective sleep quality
Time frame: through study completion, an average of 6 months
Postpartum depression diagnosis (clinical threshold)
Time frame: From the birth of the child to the end of the study (12 weeks)
Objective measure of chronic stress
Time frame: Two measurements: During pregnancy (T1) and 12 weeks postpartum (T3)
Subjective chronic stress levels
Time frame: Three times: During 1st visit, at 6 weeks postpartum and 12 weeks after birth
Daily activity changes induced by tVNS
Time frame: From the recruitment through first 12 weeks of postpartum period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2024.
- Individual participant dataSharing planned: Yes. The individual participant data (IPD) will be anonymized and shared in accordance with the GDPR. Data will be shared to the extent that re-identification is not possible.
Related trials for Postpartum Depression (PPD)
Recruiting
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
Postpartum Depression (PPD)
Recruiting
Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal Depression
Depression During Pregnancy, Postpartum Depression (PPD)
RecruitingEarly Phase 1
A Web-based Intervention Program for Postpartum Depression
Postpartum Depression (PPD), Web-based Intervention
Recruiting
The Goal is to Examine the Impact of Doula-delivered, Nurse-coordinated Postpartum Care Among Individuals With Preterm Births <34 Weeks' Gestation Requiring NICU Admission.
Doula Support, Postpartum
Not yet recruitingObservational study
AI-Enabled Wearable Monitoring for Detection of Postpartum Depression and Anxiety
Postpartum Depression (PPD), Postpartum Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Birgit Derntl, Prof., PhD principal investigator
University Hospital Tuebingen
Nils Kroemer, Prof., Dr. rer. nat. principal investigator
University Hospital Tuebingen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcutaneous vagus nerve stimulation in people with Postpartum Depression (PPD) and Postpartum Anxiety, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julia Siodmiak, M.sc. (+49 (0)7071 29-85736, julia.siodmiak@med.uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
tVNS-induced changes in postpartum depression symptoms (time frame: Measured during pregnancy (T1), 6 weeks after birth (T2), and 12 weeks after birth (T3)]). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024.